User Fee Revenues
PDUFA IV specifies that FDA shall collect fee revenues from establishment, product, and application fees. The statute specifies revenue amounts for each of these categories and specifies that the statutory amounts are to be adjusted in each fiscal year for inflation, workload, and statutory drug safety increases. FDA then establishes fees at the beginning of each fiscal year so that the total revenue collected approximates the adjusted statutory total fee amount.
Under PDUFA, fees collected and appropriated, but not spent by the end of a fiscal year, continue to remain available for FDA to spend in future fiscal years. The balances carried over from year to year are described in the section on carryover balances beginning on
The following table provides a breakout of user fees collected by fee category during the past two fiscal years, and also reflects estimates of receivables.
FOOD AND DRUG ADMINISTRATION
STATEMENT OF PDUFA USER FEE REVENUES BY FEE SOURCE
As of September 30, 2009
Fiscal Year FY 2008 FY 2009 Fees Collected: Application Fees $154,164,400 $182,835,800 Establishment Fees $168,357,952 $174,483,232 Product Fees $157,763,524 $155,917,120 Total Fees Collected: $480,285,876 $513,236,152 Fees Receivable: Application Fees $281,800 $34,900 Establishment Fees $589,050 $638,400 Product Fees $589,050 $643,680 Total Fees Receivable: $1,065,940 $1,316,980 Total User Fee Revenues: $481,351,816 $514,553,132
Note that user fee revenues are reported in the year the fee was originally due—referred to as cohort years. For example, a fee due in FY 2008, even if it is received in FY 2009, is attributed to FY 2008 revenues. Totals reported for each year are net of any refunds for that year.
FDA bills the uncollected fees twice a year – August and November. In order to ensure the quality of the information provided in this financial report, FDA updates prior year numbers each year.
Next Section: Obligation of User Fee Revenues